

Biosafety and Public Outreach in Synthetic Biology



CI-SYN-BIO

CQSY



GEN-AU
GENOMFORSCHUNG IN ÖSTERREICH

SynbioSafety EU-China

国家自然科学基金委员会
National Natural Science Foundation of China

FWF

Der Wissenschaftsfonds.

Markus Schmidt, IDC,
Biosafety Working Group
DG Sanco, Brussels
18-19th March, 2010

*„What I cannot create,
I do not understand“*



Richard Feynman

but...

Do I understand what I can create?

Subfields of contemporary SB

1. DNA Synthesis
2. DNA based bio-circuits
3. Minimal genome
4. Protocells
5. Chemical SB



http://www.synbiosafe.eu/uploads/pdf/Schmidt_etal-2009-SSBJ.pdf

3 main biosafety challenges

- Can we (still) assess the risks from new SB products, functions and systems?
- How can we improve safety through SB biosafety engineering?
- What happens if non-professionals start using SB?

http://www.synbiosafe.eu/uploads/pdf/Schmidt_etal-2009-SSBJ.pdf

Case-by-case

	DNA synthesis	DNA-based biocircuits	Minimal genome	Proto-cells	Chemical SB
Risk assessment					
Biosafety engineering					
DIYBio - diffusion					

Chapter 6 Do I Understand What I Can Create?

Biosafety Issues in Synthetic Biology

Markus Schmidt


Contents


6.1	Introduction	
6.1.1	Biosafety vs Biosecurity	
6.1.2	The Different Flavors of Synthetic Biology	
6.2	Biosafety Issues	
6.2.1	Risk Assessment	
6.2.2	Biosafety Engineering	
6.2.3	Diffusion to Amateur Biologists	
6.3	Conclusions	
	References	

Markus Schmidt · Alexander Kelle
 Agomoni Ganguli-Mitra · Huib de Vriend
 Editors


Synthetic Biology

The technoscience and its societal consequences




 Springer

Risk assessment




Mini-chromosomes in crop plants

- Chromatin Inc. developed a mini-chromosome
- Has centromere and telomere, up to 200kbp
- In corn and sugarcane
- Licensed to Bayer CropScience and Syngenta



Protocells: life from the bottom up



Liposome, made from phospholipids, grows and divides.

Semi-synthetic cell

Szostak et al. 2001, Nature

Zurbruggen 2003. Vaccine

Chiarabelli et al. 2009 Curr Opinion Biotech

Artificial reefs under Venice



Protocells to produce calcium carbonate: TED 2009. Rachel Armstrong: Architecture that repairs itself

Social and ethical checkpoints for bottom-up synthetic biology, or protocells

Mark A. Bedau · Emily C. Parke · Uwe Tangen ·
Brigitte Hantsche-Tangen

Critical Reviews in Toxicology, 38:1–11, 2008
Copyright © 2008 Informa Healthcare USA, Inc.
ISSN: 1040-8444 print / 1547-6898 online
DOI: 10.1080/10408440701524519

informa
healthcare

Lipid Vesicles as Membrane Models for Toxicological Assessment of Xenobiotics

Helmut H. Zepik and Peter Walde
Department of Materials, ETH Zürich, Zürich, Switzerland

Elisabet L. Kostoryz, Jim Code, and David M. You
University of Missouri, Kansas City, Missouri, USA

RECENT ADVANCES WITH LIPOSOMES AS PHARMACEUTICAL CARRIERS


Vladimir P. Torchilin

Abstract | Liposomes — microscopic phospholipid bubbles with a bilayered membrane structure — have received a lot of attention during the past 30 years as pharmaceutical carriers of great potential. More recently, many new developments have been seen in the area of liposomal drugs — from clinically approved products to new experimental applications, with gene delivery and cancer therapy still being the principal areas of interest. For further successful development of this field, promising trends must be identified and exploited, albeit with a clear understanding of the limitations of these approaches.

Biosafety engineering with Chemical SB

chemical monopoly






Forms of orthogonality

- XNA (Herdewijn, Marliere)
- Enlarged genetic alphabet (Benner, Romesberg)
- Reassigning triplet codons (Chin, Budisa)
- Quadruplet codons (Schultz, Chin)
- Non-canonical aminoacids in proteins (Luisi, Budisa, Marliere)
- Mirror life (Church)

Parallel world



Schmidt 2010. Xenobiology: a new form of life as the ultimate biosafety tool. BioEssays
http://www.markusschmidt.eu/pdf/Xenobiology-Schmidt_Bioessays_201004.pdf

Xenobiology: A new form of life as the ultimate biosafety tool

Markus Schmidt*

Organisation for International Dialogue and Conflict Management, Kaiserstr.

nature
biotechnology

Synthetic biologists try to engineer useful biological systems that do not exist in nature. One of their goals is to create a new form of life that is safe and secure.

Syst Synth Biol (2009) 3:77–84
 DOI 10.1007/s11693-009-9040-9

Genome engineering

The farther, the safer: a manifesto for securely navigating synthetic species away from the old living world

Philippe Marlière

church²

Engineering genetic material have pursued increasingly challenging. The genetic engineer have grown to encompass new extremes of genome engineering. Today, our capacity to generate larger *de novo* assemblies decreases in manufacturing cost. We are also witnessing potential for genome engineering approaches targeting large numbers of species. Genome engineering with unprecedented levels of design originality and scale world and the diversity of applications for societal benefit.

009)

791

Toward Safe Genetically Modified Organisms through the Chemical Diversification of Nucleic Acids

by Piet Herdewijn^{a)} and Philippe Marlière^{b)}

^{a)} Laboratory for Medicinal Chemistry, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven

^{b)} Isthmus Sarl, 31 rue Saint Amand, F-75015 Paris


DIYbio

FRIDAY, AUGUST 22, 2008

Science without Scientists

As molecular tools get cheaper, and the know-how for using them more widely distributed, I think we're going to see a renaissance in science. The peculiar feature of this renaissance is that its going to take place outside of "science proper", away from the universities which dominate now, and funded out-of-pocket by enthusiasts without PhDs.

SUBSCRIBE NOW



Enter your email address to subscribe:




Foto credits: Rob Carlson. See: <http://www.synthesis.cc/2010/03/garage-biology-in-silicon-valley.html>

Austrian highschool




<http://hlfs.ursprung.at/>


Catalase with non-canonical amino acids




Catalase
Bacillus subtilis 1A55



Methionine



Ethionine



Norleucine

<https://gbtpilot.plus.sbg.ac.at/tiki-index.php?page=Synthetische+Biologie+am+Prüfstand+der+Schule&structure=SynBio>



International dialogue



www.idialog.eu/fwf/

Science and Society

COSY: Communicating Synbio



Scientists a step closer to producing fuel from bacteria

Scientists at the University of Sheffield have shown how bacteria could be used as a future fuel. The research could have significant implications for the environment and the way we produce sustainable fuels in the future.

Like all living organisms, bacteria sustain themselves through their metabolism, a huge sequence of chemical reactions that transform nutrients into energy and waste.

Using mathematical computer models, the Sheffield team have mapped the metabolism of a type of bacteria called *Nostoc*. *Nostoc* uses nitrogen and, in doing so, releases hydrogen that can then be potentially used as fuel. Fixing nitrogen is an energy intensive process and it wasn't entirely clear exactly how the bacterium produces the energy it needs in order to perform how the new computer system has been used to map out how this happens.

Until now, scientists have had difficulties identifying bacterial metabolic pathways. The bacterial metabolism is a huge network of chemical reactions, and even the most sophisticated techniques can only measure a small fraction of its activity.

Dr Guido Bogardet, from the University's Department of Computer Science, who led the study, said: "The research uncovered a previously unknown link between the energy machinery of the *Nostoc* bacterium and its core nitrogen metabolism. Further investigation



Results COSY

- Synbio specifics get lost in communication process: „old wine in new bottles“
- First neutral, then polarized opinions
- Risk the same for everybody
- Sceptics don't „buy“ promised benefits

Syst Synth Biol (2009) 3:19–26
DOI 10.1007/s11693-009-9031-x

ORIGINAL RESEARCH ARTICLE

Communicating Synthetic Biology: from the lab via the media to the broader public

Nicole Kronberger · Peter Holtz · Wolfgang Kerbe ·
Ewald Strasser · Wolfgang Wagner

Received: 30 April 2009 / Revised: 18 June 2009 / Accepted: 29 June 2009
© The Author(s) 2009. This article is published with open access at Springerlink.com

Abstract We present insights from a study on commu- new technology will be met with similar pu

Documentary film





www.synbiosafe.eu/DVD

Science, Fiction, and Science Fiction



Victimless leather



SymbioticA

Cinema and Synthetic Biology


 **CISYNBIO**
CINEMA AND SYNTHETIC BIOLOGY

[Share this Site!](#)

HOME PROJECT AIM PROJECT TEAM LINKS CONTACT



Project Name: CISYNBIO - Cinema and Synthetic Biology
Duration: August 2009 to August 2012
Coordinator: Dr. Markus Schmidt (IDC). [More about the team >>](#)
Funding: CISYNBIO is funded with 285k€ by the Austrian GEN-AU ELSA III programme



The order of the reference list and citations have been corrected in this PDF.



LET'S MAKE A MAMMOTH

Evolution assumes that extinction is forever. Maybe not. **Henry Nicholls** asks what it would take to bring the woolly mammoth back from the dead.

In 1990 the late Michael Crichton gave the idea of reviving extinct species a slickly plausible and enormously entertaining workout in his novel *Jurassic Park*. At that time the longest genome that had ever been sequenced was that of a virus. The best part of 20 years on, hundreds of animal genome sequences have been published. This week, for the first time, the genome of something undeniably charismatic and definitively extinct joins the list: the mammoth (*Mammuthus primigenius*). If you want to bring a species back to life, the mammoth would be almost as dramatic as a dinosaur. And unlike *Dinocarnaurus rex*, the mammoth has close living relatives to lend a hand.

It is a fair bet that a complete genome and closely related species would make it easier to pull a Crichton on a mammoth than on a dinosaur. But easier is far from easy. To put flesh on the bones of the draft sequence — to go from a genome to a living, breathing beast — would require you to master, at the very least, the following steps: defining exactly the sequence or sequences you want for your creature; synthesizing a full set of chromosomes from these sequences; engaging them in a nuclear envelope; transferring that nucleus into an egg that would support it; and getting that egg into a womb that would carry it to term. None of those steps is currently possible. From getting a definitive sequence to harvesting eggs from an elephant there are all-but-insurmountable obstacles at every stage,

and no evidence that anyone is going to work very hard to solve them. But do any of them actually make the dream impossible?

The sequence

The first step in this mammoth challenge is to obtain a sequence good enough for us to contemplate using it as the basis for a living being. The sequencing of long-dead DNA such as that of mammoths uses fragments at various levels of degradation. To detect and correct the base-pair changes that can occur after death and to avoid the inevitable errors involved in assembling millions of these tiny fragments into a coherent sequence, it is necessary to sequence much more than a single genome's worth of DNA. "If we want fewer than 1 error in 10,000 base pairs — a reasonable quality genome — we would need to sample in the order of 12-fold coverage," says Svante Pääbo, director of the genetics department at the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany, who has worked on Neanderthal genomes. The genome published today has roughly 0.7-fold coverage. "Reasonable quality" for science does not mean the sort of genome you would want to live with in a human genome that error rate would mean 300,000 mutations.

Coverage can be improved as long as there's the money to do it, but old samples offer particular challenges: a lot of contamination by bacterial, fungal and other species' DNA.




Darwin200

Thirty-five-fold coverage, which Pääbo regards as good as it gets, would be "extremely costly and extremely time-consuming", according to Erik Willerslev, head of the Ancient DNA and Evolution Group at the University of Copenhagen. Cheaper sequencing, however, and the possibility of better preserved and prepared samples, mean that these expenses of cost and time will shrink. Willerslev sees nothing to stop researchers from producing a mammoth genome as good as any genome today at some point in the future. Whether such a genome would be good enough for a living being remains a somewhat open question — but with time and effort, it's plausible that a sufficiently error-free genome can be arrived at.

A sequence in its own, though, isn't enough: researchers will need to work out exactly how it divides up into chromosomes. The obvious solution would be to test up the number of chromosomes in an intact mammoth cell and sift through the genomic data looking for their beginnings and endings. But even the very best mammoth material falls short of this kind of preservation (see "You need to do more than that"). "We have no idea — yet — how many chromosomes mammoths had," says Hendrik Poinas, a geneticist at McMaster University in Ontario, Canada. Kerstin Lindblad-Toh, co-director of the genome sequencing and analysis programme at the Broad Institute in Cambridge, Massachusetts, says that the institute will release a sequence of the African elephant (*Loxodonta africana*) to seven-fold coverage some time in 2009. When they do, the mammoth geneticists

"Genome synthesis is further developed today than genome sequencing was when Crichton wrote Jurassic Park."

www.bio-fiction.com



BIO:FICTION

SCIENCE, FILM & ART FESTIVAL, VIENNA, MAY

2011



This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.